Back to results
US 2018/0002399 A1Published application
Fgfr1 extracellular domain combination therapies
AssigneeFive Prime Therapeutics, Inc.
InventorsLi Long, Thomas Brennan
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeFive Prime Therapeutics, Inc.
InventorsLi Long, Thomas Brennan
Estimating the term…
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
A method of treating lung cancer in a human subject comprising administering to the subject an effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule and at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, and topotecan, wherein the FGFR1 ECD fusion molecule comprises an FGFR1 ECD comprising an amino acid sequence selected from SEQ ID NOs:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.